# Declan G. Murphy

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/declan-g-murphy/

## Facts

| Field | Value |
| --- | --- |
| Citations | 21,335 |
| Field | Prostate Cancer Diagnosis and Treatment |
| h-index | 69 |
| i10-index | 240 |
| Last Known Institution | The University of Melbourne |
| OpenAlex ID | https://openalex.org/A5101702288 |
| ORCID iD | https://orcid.org/0000-0002-7500-5899 |
| Works | 554 |

## Researcher papers

Showing 12 of 15.

- [Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study](https://scholariq.org/papers/prostate-specific-membrane-antigen-pet-ct-in-patients-with-high-risk-prostate/)
- [\[177Lu\]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study](https://scholariq.org/papers/177lu-psma-617-radionuclide-treatment-in-patients-with-metastatic-castration/)
- [Sensitivity, Specificity, and Predictors of Positive 68 Ga–Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis](https://scholariq.org/papers/sensitivity-specificity-and-predictors-of-positive-68-ga-prostate-specific/)
- [Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer—Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis](https://scholariq.org/papers/gallium-68-prostate-specific-membrane-antigen-positron-emission-tomography-in/)
- [The Lancet Commission on prostate cancer: planning for the surge in cases](https://scholariq.org/papers/the-lancet-commission-on-prostate-cancer-planning-for-the-surge-in-cases/)
- [Dosimetry of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes](https://scholariq.org/papers/dosimetry-of-sup-177-sup-lu-psma-617-in-metastatic-castration-resistant-prostate/)
- [Systematic Review and Cumulative Analysis of Perioperative Outcomes and Complications After Robot-assisted Radical Cystectomy](https://scholariq.org/papers/systematic-review-and-cumulative-analysis-of-perioperative-outcomes-and/)
- [The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study](https://scholariq.org/papers/the-additive-diagnostic-value-of-prostate-specific-membrane-antigen-positron/)
- [Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019](https://scholariq.org/papers/management-of-patients-with-advanced-prostate-cancer-report-of-the-advanced/)
- [Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of <sup>177</sup>Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer](https://scholariq.org/papers/long-term-follow-up-and-outcomes-of-retreatment-in-an-expanded-50-patient-single/)
- [PSMA and FDG-PET as predictive and prognostic biomarkers in patients given \[177Lu\]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial](https://scholariq.org/papers/psma-and-fdg-pet-as-predictive-and-prognostic-biomarkers-in-patients-given-177lu/)
- [Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers](https://scholariq.org/papers/interim-results-from-the-impact-study-evidence-for-prostate-specific-antigen/)

## Researcher topics

- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)
- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Radiopharmaceutical Chemistry and Applications](https://scholariq.org/topics/radiopharmaceutical-chemistry-and-applications/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)

## Researcher university

- [The University of Melbourne](https://scholariq.org/institutions/the-university-of-melbourne/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.